Opdualag sets its sights on lung
After several disappointments Bristol at last turns its Lag3/PD-1 combo to first-line lung cancer.
Pfizer makes haste to go EZ
The company sticks with EZH2, despite others adding EZH1 inhibition.
Pfizer takes on Merck in a new checkpoint
Pfizer’s LILRB1 x LILRB2 bispecific is about to enter the clinic.
The month ahead: August’s remaining events
Following its odronextamab knockback, Regeneron now faces a delay to linvoseltamab.
Blood cancer gene therapies enter the clinic
First-in-human trial initiations feature Interius, Umoja and Vironexis.
Nuvalent’s next battleground is HER2
NVL-330 features among the latest crop of industry projects newly into human trials.
Crunch time for Bristol’s TIGIT bet
Now in Bristol’s hands, BMS-986442 is set to deliver its first clinical data.
